Delving into the Latest Updates on Zuventus Healthcare Ltd. with Synapse

概览

关联

44

项与 Zuventus Healthcare Ltd. 相关的临床试验

CTRI/2024/03/064100 / Recruiting临床4期

A multicentric, open label study to evaluate the safety and efficacy of fixed-dose combination of Efonidipine 40 mg and Telmisartan 40 mg tablets in the management of Stage II hypertension. - NIL

开始日期2024-03-20

申办/合作机构

Zuventus Healthcare Ltd.

CTRI/2023/06/054295 / CompletedN/A

An open-label, balanced, randomized, two-treatment, two-sequence, two-period, single dose, crossover, oral bioequivalence study of Test Product, Edoxaban 60 mg film-coated tablets (Zuventus Healthcare Limited, India) with Reference Product, Lixiana (Edoxaban) 60mg film coated tablets (Daiichi Sankyo Europe GmbH, 81366 Munich, Germany) in healthy, adult, human subjects under fasting conditions. - Nil

开始日期2023-06-29

申办/合作机构

Zuventus Healthcare Ltd.

CTRI/2023/01/048826 / Active, not recruiting临床3期

A randomized, multi-centric, comparative, parallel, open-label, active-controlled, Phase III trial study to demonstrate the non-inferiority of Trelagliptin 100mg once weekly to Vildagliptin 50 mg twice daily in the management of Type-2 Diabetes Mellitus.

开始日期2023-01-10

申办/合作机构

Zuventus Healthcare Ltd.

100 项与 Zuventus Healthcare Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Zuventus Healthcare Ltd. 相关的专利（医药）

登录后查看更多信息

9

项与 Zuventus Healthcare Ltd. 相关的文献（医药）

2023-10-01·Indian Journal of Tuberculosis

Aviptadil: A promising treatment option for acute respiratory distress syndrome

Letter

作者: Jaychandra, A ; Vora, Agam ; Singh, B P ; Kandi, Subhankar ; Behera, D ; Najib, Rayees ; Arora, V K ; Dewan, Bhupesh ; Koul, Parvaiz ; Ahmad, Sadiq ; Kar, Arindam ; Samaria, J K ; Katiyar, S K ; Mehta, Parthiv ; Najeeb, Rukhsana ; Nazir Shah, Naveed ; Faisal, Mir ; Jain, N K

2015-01-01·Indian Journal of Pharmaceutical Sciences4区 · 医学

Design, development and optimization of s (-) Atenolol floating sustained release matrix tablets using surface response methodology

4区 · 医学

Article

作者: Gunjal, P T ; Gharge, V S ; Shah, M N ; Gurjar, M K ; Pimple, S V ; Shinde, M B

The objective of this present investigation was to develop and formulate floating sustained release matrix tablets of s (-) atenolol, by using different polymer combinations and filler, to optimize by using surface response methodology for different drug release variables and to evaluate the drug release pattern of the optimized product. Floating sustained release matrix tablets of various combinations were prepared with cellulose-based polymers: Hydroxypropyl methylcellulose, sodium bicarbonate as a gas generating agent, polyvinyl pyrrolidone as a binder and lactose monohydrate as filler. The 3(2) full factorial design was employed to investigate the effect of formulation variables on different properties of tablets applicable to floating lag time, buoyancy time, % drug release in 1 and 6 h (D1 h,D6 h) and time required to 90% drug release (t90%). Significance of result was analyzed using analysis of non variance and P < 0.05 was considered statistically significant. S (-) atenolol floating sustained release matrix tablets followed the Higuchi drug release kinetics that indicates the release of drug follows anomalous (non-Fickian) diffusion mechanism. The developed floating sustained release matrix tablet of improved efficacy can perform therapeutically better than a conventional tablet.

2011-01-01·Gastroenterology Research and Practice4区 · 医学

Lafutidine 10 mg versus Rabeprazole 20 mg in the Treatment of Patients with Heartburn-Dominant Uninvestigated Dyspepsia: A Randomized, Multicentric Trial

4区 · 医学

ArticleOA

作者: Dewan, Bhupesh ; Philipose, Nisha

Background. Empirical therapy with antisecretory agents like PPIs and H2RAs has long been the traditional approach in the initial management of uninvestigated dyspepsia.Aim. The objective of the study was to examine relief of dyspepsia with lafutidine, a second-generationH2-RA, and rabeprazole and to compare their efficacy.Methods. This was a randomized, open, comparative trial in adult uninvestigated dyspeptic patients, who had at least moderate severity of symptoms, defined as a score of≥4 on a 7-point global overall symptom (GOS) scale, and were randomized to receive once daily either lafutidine 10 mg or rabeprazole 20 mg for 4 weeks.Results. A total of 236 patients were enrolled, out of which 194 patients were included in the analysis. At the end of week 4, a significant difference was observed for symptom relief (lafutidine 89.90% versus rabeprazole 65.26%,P<.01) and symptom resolution (lafutidine 70.71% versus rabeprazole 25.26%,P<.01). Both the drugs were well tolerated.Conclusion. Both lafutidine and rabeprazole provide symptom relief in patients with heartburn-dominant uninvestigated dyspepsia. The present study confirms the appropriateness of lafutidine as an empiric treatment and superior efficacy for primary care practice patients with dyspepsia.

100 项与 Zuventus Healthcare Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Zuventus Healthcare Ltd. 相关的转化医学

登录后查看更多信息